Royalty Report: Drugs, Cancer, Antibody – Collection: 26237

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Cancer
  • Antibody
  • Pharmaceuticals
  • Therapeutic
  • Biotechnology
  • HIV / AIDs
  • Drug Discovery
  • Disease
  • Viral Infection
  • Delivery
  • cell therapy

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26237

License Grant
The agreement granted exclusive development and commercialization rights to the Licensor's fully human, immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014 for the greater Chinese market.
License Property
The mAb is novel, proprietary, and fully human. The Licensor is currently developing production quality cell lines for their anti-PD-L1 antibody, STI-A1010, which will lay the foundation for Investigational New Drug, or IND, -enabling studies in the U.S. in 2014. The Licensor anticipates that a Phase I clinical trial for their lead candidate anti-PD-L1 antibody could be initiated in 2015.  The mAb's are derived from the Licensor's proprietary G-MAB® library platform and chosen based on cancer targets.

Patent Antigen binding proteins that bind PD-L1

Field of Use
The individual mAbs discovered from the Licensor's library potentially give a multitude of therapeutic options to target and attack cancer cells. This could be either directly, such as (i) recruitment of immune effector functions, including, but not limited to, antibody-dependent cellular cytotoxicity, or ADCC, or (ii) antagonistic suppression of cellular signaling processes required for cancer proliferation and metastasis; or indirectly, via modulation host biology, such as (a) enhancement of immune activity in the tumor, or (b) normalization of the tumor microenvironment, including anti-angiogenesis for cutting off blood supplies to the tumor.

IPSCIO Record ID: 3068

License Grant
We restructured our product development collaboration with the Licensee, which involves six development programs including the HCD122 program. In exchange, the Licensee has control over the HCD122 program and the additional ongoing program, as well as the right to expand the development of these programs into additional indications outside of oncology.
License Property
HCD122 is a fully human anti-CD40 antagonist antibody intended as a treatment for B-cell mediated diseases, including malignancies and autoimmune diseases, is currently recruiting patients for a Phase 1/2 lymphoma trial. The antibody has a dual mechanism of action that involves inhibition of CD40-ligand mediated growth and survival while recruiting immune effector cells to kill CD40-expressing tumor cells through a process known as antibody-dependent cellular cytotoxicity (ADCC). CD40, a member of the tumor necrosis factor, or TNF, family of antigens, is a cell surface antigen expressed in B-cell malignancies and involved in a broad variety of immune and inflammatory responses.

IPSCIO Record ID: 359135

License Grant
Licensor entered into a license agreement with Chinese Licensee, thereby granting to Licensee exclusive rights to commercialize Licensor's monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America.
License Property
Pritumumab, a drug candidate using monoclonal antibodies for the treatment of various cancer types. Pritumumab may offer an advantage over existing treatments. Pritumumab works by binding to a target on the surface of cancer cells called ectodomain vimentin (also referred to as cell-surface vimentin). The target, generally referred to as an antigen, is prevalent in many different tumor types and is not being targeted by any other biopharmaceutical companies. By binding to this target, Pritumumab is able to make the tumor cells “known” to the body’s immune system, resulting in potentially several types of immune responses, including anti-idiotype, apoptosis, antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, leading to death of the cancer cells and overall depletion of the tumor.
Field of Use
Field of use is for the treatment of brain cancer and pancreatic cancer and exploring in its use against viruses.

IPSCIO Record ID: 307594

License Grant
The parties partnered to jointly develop and commercialize three of Licensor’s early-stage investigational bispecific antibody product candidates and enter into a discovery research collaboration for future differentiated antibody therapeutics for cancer.
License Property
Epcoritamab (DuoBody-CD3xCD20) is a bispecific antibody created using Licensor’s proprietary DuoBody technology. Epcoritamab is designed to target CD3, which is expressed on T cells and is part of the T cell receptor signaling complex, and CD20, a clinically well validated therapeutic target. CD20 is expressed on a majority of B cell malignancies, including chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). In a number of laboratory models, epcoritamab has shown highly effective killing of CD20+ tumors and induced potent tumor cell lysis across a panel of B cell tumor lines. Epcoritamab is currently evaluated in a Phase 1/2 study for multiple hematological B cell malignancies.

The companies will partner to develop Licensor’s next-generation bispecific antibody programs, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensor’s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licensee’s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensor’s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licensee’s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.

Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization.

Field of Use
The field of use is for the treatment of cancer utilizing antibodies. Bispecific antibodies (also known as dual-targeting molecules) bind to two different epitopes, either on the same or on different targets. This may improve the antibodies’ specificity and efficacy in inactivating the disease target cells.

Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.

IPSCIO Record ID: 361677

License Grant
Licensor assigned to Licensee in the Progenics Purchase Agreement, pursuant to which we have an exclusive worldwide license to develop, make, have made, import, use, sell, offer to sell or have sold products that incorporate the humanized form of the leronlimab antibody developed under the agreement.
License Property
Leronlimab, a monoclonal antibody C—C chemokine receptor type 5 (“CCR5”) receptor antagonist, to be used as a platform drug for various indications. The target of leronlimab is the immunologic receptor CCR5. The CCR5 receptor is a protein located on the surface of various cells including white blood cells and cancer cells. On white blood cells, it serves as a receptor for chemical attractants called chemokines. The CCR5 receptor is also the co-receptor needed for certain strains of HIV to infect healthy T-cells. Recent research has identified the CCR5 receptor as an important target for many disease processes, including cancer metastasis and certain immunological conditions. Leronlimab is a unique humanized monoclonal antibody.

Leronlimab binds to the second extracellular loop and N-terminus of the CCR5 receptor, and due to its selectivity and target-specific mechanism of action, leronlimab does not appear to activate the immune function of the CCR5 receptor through agonist activity. This apparent target specificity differentiates leronlimab from other CCR5 antagonists. Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor.

Field of Use
Leronlimab (PRO 140) is a CCR5 antagonist with the potential for multiple therapeutic indications, today provided an update on leronlimab (PRO140) as a single agent for maintenance of HIV viral load suppression (HIV-1 RNA < 50 copies/mL).

The latest investigative monotherapy trial has revealed sufficient data to more precisely design the pivotal Phase 3 monotherapy trial that Licensee plans to use as the basis for label expansion after the potential approval of leronlimab (PRO140) for HIV patients as a combination therapy with HAART.  The longer half-life of leronlimab may help to reduce the number of non-responders in the first ten weeks of monotherapy, if the treatment overlaps with existing regimen of leronlimab for four weeks before initiating monotherapy.  Under the current trial protocol, patients have 7 days of overlap with their HAART regimen and leronlimab before initiating monotherapy.

The U.S. Food and Drug Administration (FDA) has granted a “Fast Track” designation to leronlimab (PRO 140) as a combination therapy with HAART for HIV-infected patients.  Leronlimab (PRO 140) is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that appears to play multiple roles with implications in HIV infection, tumor metastases and immune signaling.  Leronlimab (PRO 140) has successfully completed nine Phase 1/2/3 clinical trials in over 700 people, including a successful pivotal Phase 3 trial in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients.

Field of use is to treat human immunodeficiency virus (“HIV”) patients with multiple resistance to current standard of care, COVID-19 patients, and metastatic Triple Negative Breast Cancer (“mTNBC”), among other indications.

IPSCIO Record ID: 280819

License Grant
For the Research the German Licensor grants a non-exclusive research license under Licensor Background Inventions and Licensors rights in Collaboration Data, Collaboration Materials and Collaboration Inventions, to perform its obligations under the Collaboration Plan.

For the Commercial License,  Licensor grants an exclusive, worldwide license to make, have made, use, have used, sell, have sold, offer for sale, import and have imported Licensed Products for use in the Field directed to such Licensee Target under Licensor Background Inventions, and under Licensors rights in all Patent Rights and Collaboration Inventions and Collaboration Material pertaining to such Licensee Target and Licensed Products, or the uses thereof in the Field.

License Property
Licensors HuCAL Technologies shall mean the HuCAL library and associated technologies.   The library data is for a Design of Human Combinatorial Antibody Library-Fab (HuCAL-Fab).
Field of Use
The field shall mean all therapeutic indications.  With this agreement, the Parties will collaborate in the discovery and development of human monoclonal antibodies against certain specified Licensee Targets,  to generate and characterize antibodies and optimize those antibodies and  use their expertise in developing antibodies in pre-clinical and clinical settings.

The two companies will collaborate on the development of human antibodies for the treatment of cancer.

IPSCIO Record ID: 291107

License Grant
Collaborator hereby grants to Licensee of Ireland an exclusive license (exclusive even as to Collaborator), with the right to sublicense, under the Collaborator Technology, to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize and have Commercialized Antibodies and Products in the Territory.
License Property
Product means any pharmaceutical product containing one or more Antibodies whose manufacture, use, sale, offer for sale or importation by Licensee in a given country in the Territory is covered by a Valid Claim under a Collaborator Patent Right or Sponsored Research Patent Right in such country.

Collaborator Patent Right means any Patent Right that (a) is Controlled by Collaborator or any of its Affiliates as of the Effective Date (including the Collaborator Patent Rights that comes into the Control of Collaborator or any of its Affiliates during the Term (other than through the grant of a license by Licensee) and (b) claims or discloses any (i) Antibody or Product (including the composition of matter thereof), (ii) method of making any Antibody or Product or materials used in any method of making any Antibody or Product, or (iii) methods of using any Antibody or Product.

Collaborator Technology means the Collaborator Patent Rights and Collaborator Know-How.

Patent Rights means any and all (a) issued patents, (b) pending patent applications, including all provisional applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon, (c) patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor’s certificates, (e) other forms of government-issued rights substantially similar to any of the foregoing and (f) United States and foreign counterparts of any of the foregoing.

1. The Identification and Selection of individual Human B cell donors
Pre-requisites to I-STAR screen
• Initiate blood (B cell) collection program for non-small cell lung carcinoma.
• 200 donors to be screened serologically prior to selection for I-STAR memory B cell activation.
• Perform serum binding assay against NSCLC tumor cell lines.
• Selection of top 50 subjects/ B cell donors with serum reactivity against NSCLC tumor cell lines for IgG+ memory B cell isolation and activation (I-STAR platform). Subject selection to be done by Pfizer/ Theraclone joint project team.

2. I-STAR process for selection of native human bNAbs
I-STAR Antibody Discovery Platform
• Perform activation of short-term memory B cell cultures (B cell expansion and differentiation) from a total of 50 selected individuals.
• 2000-20,000 native human memory B cell clones from each of  50 selected donors to be activated in vitro in preparation for screening assay.
• Perform a two step screening process to identify NSCLC binding antibodies.
o Primary screening by a high-throughput cell binding assay with NSCLC tumor cell lines using supernatant from cultured B cells. Primary screens will provide initial identification of antibody binding of up to 10 tumor cell lines. The NSCLC tumor cell lines will be chosen by the Pfizer/ Theraclone joint project team. Screening will utilize pools of three to four tumor cell lines to increase throughput.
o Perform secondary screens on tumor cell line binding antibodies. Secondary screens will assess binding to NSCLC tumor cell lines by suitable techniques, and lack of binding to a normal cell line. Normal cells lines will be chosen by the joint project team.
• Deep sequencing of up to 2,880 hit wells to be performed and sequence analysis allowing clustering of hits into bins (based on V-region (VH / VL sequences). All DNA and amino acid sequences delivered to Pfizer.
• Joint project team to prioritize up to 200 mAbs for small scale expression.

3. Generation of recombinant mAh protein and re-screening against target cells
• Generation (expression and purification) of transiently transfected full-length, human mAbs from mammalian cells in an appropriate human IgG format for up to 200 target antigen positive V-region hits.
• Initial characterization of recombinant mAbs to confirm NSCLC tumor cell line binding, internalization and binding to disaggregated cells from PDX tissue.
• Develop an internalization assay based on cell killing by auristatin conjugates. Several antibodies, including anti-EGFR, anti-HER2, anti-transferrin receptor and TCN-462 will be evaluated as potential internalization control antibodies.

4. Generation of large scale recombinant mAh protein, characterization data and re-screening against targets
• Selection of up to 50 unique antibodies that the joint project team regards suitable for further analysis
• Selection criteria
o Binding to NSCLC PDX tissue
o Binding to cancer cells in vitro, Ko determination by tumor cell binding
o Lack of binding to normal cell lines
o Internalization into NSCLC tumor cell lines
• mAb expression and purification at Theraclone – highest 50 prioritized mAbs at 5 – 20 mg scale. Additional prioritized mAbs purified at 5-20 mg scale subject to joint project team approval.
• Quality control A280, SDS-PAGE, CIEX, SEC, target I antigen binding profile, endotoxin analysis

Field of Use
I-STAR technology relates to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

IPSCIO Record ID: 203490

License Grant
This agreement is to develop and commercialize certain of the antibodies produced and evaluated by the Parties pursuant to such collaborative relationship and/or other antibodies generated against the target proteins identified within the collaboration and selected by Licensee for development, and the Parties desire for Licensor to have all rights to those targets and antibodies coming out of the collaborative research that Licensee does not elect to further develop.

For the Screening license, Licensor grants a non-exclusive license under the Licensors Technology and Licensors interest in any Joint Know-How in the United States solely as necessary to carry out the Research hereunder during the Research Term.  Such license shall not be sublicensable.

For the Development and Commercialization license, Licensor grants an exclusive license, with the right to sublicense, under the Licensed Know-How and the Licensed Patents to generate and screen Licensees Mabs; and create Derivatives of Selected Mabs and Licensee Mabs, and develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products for use in the Commercial Field in the Territory.

And, Licensor grants an exclusive license, with the right to sublicense, under the Licensed Know-How and the Licensed Patents to use the Selected Targets to generate and screen Licensee Mabs, and develop Licensed Mabs in the Commercial Field in the Territory during the Term.

License Property
Licensor has proprietary immunization and other methods for generating Mabs against cell surface proteins, and possesses certain proprietary cell lines or will acquire cell lines which have cell surface proteins with relevance to ovarian cancer.

Licensor Technology shall mean any Know-How that is and all Patents claiming inventions that are useful or necessary to generate and to screen Mabs binding to a Molecular Target, including without limitation methods of immunization, methods for maintaining and handling cell lines expressing Mabs, production and freezing media, and antibody screening facilitation tools including without limitation CellArrayâ„¢,  controlled by Licensor as of the effective date and during the term, and disclosed by Licensor to Licensee during the Term.

Joint Know-How shall mean any Know-How jointly invented by both Parties in the conduct of the Research, invented by Licensor in the conduct of the Research as a direct result of its use of Licensees Technology, or, invented by Licensee in the conduct of the Research as a direct result of its use of Licensors Technology.

Licensed Product shall mean any pharmaceutical product containing a Licensed Mab.

Cytotoxic Compound shall mean any Cytotoxic compound and all variants, fragments or derivatives thereof, whether produced by a botanical source, natural fermentation or chemical synthesis,  which is, in any case, controlled by Licensee.

Naked Mab Licensed Product shall mean any Licensed Product that is not a Cytotoxin-Coupled Licensed Product.

Antigen shall mean any protein, peptide or carbohydrate or other composition, and/or any fragment, peptide and/or epitope thereof which causes an immune response that produces antibodies.

Field of Use
The Major Indication shall mean an one of prostate cancer, breast cancer, lung cancer, colorectal cancer, non-Hodgkins lymphoma, bladder cancer, melanoma, uterine cancer, leukemia, kidney cancer, head and neck cancer, pancreatic cancer or ovarian cancer.

The Commercial Field shall mean therapeutic products employing Mabs, alone or in conjunction with other ingredients, to treat cancer in humans.

IPSCIO Record ID: 27119

License Grant
The Company entered into an exclusive worldwide licensing agreement with the Licensor, government public health organization, for mesothelin mab.
License Property
Mesothelin Mab targets mesothelin receptors on cancer cells and delivers a cytotoxin to destroy the cancer cell while leaving normal cells alone.  Mesothelin Mab is expected to enter Phase I clinical studies in the later part of 1999. Mesothelin Mab specifically targets those tumors that express the mesothelin antigen on the surface of cancer cells.  Phase I to be initiated in 4th Quarter 1999.
Field of Use
Cancer Indication Ovarian, Head, Neck, Mesotheliomas.

IPSCIO Record ID: 368653

License Grant
For the options and commercial licenses, the Licensor of Switzerland, an international community of scientists focused on cancer research, grants a Non-exclusive, worldwide license, with rights to grant sub-licenses, under Licensor Patent Rights and Know-How to research, develop, make, have made, use, import, offer for sale, sell and have sold Licensed Products in the Field.
License Property
Licensor owns or has the rights to patents including those relating to Full length Antigens and Part Length Antigens.

Full Length Antigens shall mean the full length protein forms of the Licensor Antigens NY-ES0-1, NY-BR-1 and NY-C0-58.

Part Length Antigens shall mean Polypeptide Sequence forms of the Licensor Antigens MAGE-A3, Melan-A, and SSX2.

Field of Use
Agreement covers potential antigens being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma.

These antigens, previously identified and characterized immunologically by Licensor , will add to new Licensee development programs for a range of cancer types. NY-ESO-1, MAGE3, and MelanA, in particular, are being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma in an extended series of Phase I/II programs conducted by the Licensor and its collaborators.

This agreements focus is cancer immunotherapy.

IPSCIO Record ID: 322463

License Grant
Licensor sold Leronlimab to Licensee where Licensee is responsible for all development, manufacturing and commercialization efforts.
License Property
Leronlimab (PRO 140) is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including certain liver diseases.

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control.  Blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer.

Field of Use
The field of use is for the treatment in HIV infection, tumor metastases, and other diseases including certain liver diseases.

HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection.
Metastasis means that cancer spreads to a different body part from where it started.
Liver cancer is the growth and spread of unhealthy cells in the liver.

Licensee is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.

IPSCIO Record ID: 318779

License Grant
In connection with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Option Agreements were terminated and a royalty payment from the sale of IRX-2 was agreed upon to the Collaborator for a period of time.
License Property
IRX-2 is a novel cytokine-based therapy. IRX-2 active constituents, namely Interleukin-2 (IL-2) and other key cytokines are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. IRX-2 is naturally derived from human blood cells.

IRX-2 is an allogeneic, reproducible, primary, cell-derived biologic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as a subcutaneous injection around lymph node beds.
IRX-2 is produced under current good manufacturing practices, or cGMP, following stimulation of a specific population of human peripheral blood mononuclear cells (PMBC) using a specified mitogen. These cells consist of lymphocytes (T cells, B cells, NK cells) and monocytes. Cytokine production induced by the employed mitogen mimics that seen after brisk stimulation of human immune cells by an immunogenic pathogen or an infection. PBMCs are obtained from FDA-licensed blood banks meeting all criteria for further human use.

Field of Use
The field of use is for the treatment of cancer relating to advanced head and neck squamous cell cancer.

The Licensee is a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer.

IPSCIO Record ID: 27803

License Grant
Licensor grants the Swiss Licensee, an exclusive, non-transferable  license or sublicense, as applicable, under the Licensor IP to Develop, Manufacture and Commercialize Licensed Antibodies and Products in the Territory and in the Field.

The Licensor and the Licensee formed a global alliance focused on novel immuno-therapeutics using the Licensor's proprietary Retrocyte Displayâ„¢ antibody discovery platform. The collaboration is initially focused on the development of checkpoint modulator antibodies directed against GITR, OX40, LAG-3 and TIM-3.

License Property
The Licensor is an immunology company developing a series of Checkpoint Modulators for the treatment of patients with cancer, infectious diseases, and other immune disorders, heat shock protein (HSP)-based vaccines, and immune adjuvants.

LAG-3 is a checkpoint protein expressed on the surface of certain cells of the immune system. LAG-3 (lymphocyte-activation gene 3) modulates signaling between immune cells and their targets. When LAG-3 is activated, the immune response is suppressed. Antibodies that block LAG-3 can block this inhibitory signal, thereby boosting the immune system’s response against cancer cells. LAG-3 acts synergistically with other checkpoint modulators. This suggests antibodies against LAG-3 may be valuable as combination therapies.

TIM-3 is a checkpoint receptor found on certain immune cells. TIM-3 stands for T-cell immunoglobulin and mucin domain-3. To prevent hyperactivation, natural ligands binding to TIM-3 reduce the activity of these immune cells. In some types of cancer, T cells express elevated levels of TIM-3, which results in excessive immune suppression. Blocking TIM-3 could stimulate immune responses and promote immune-mediated clearing of cancer cells. TIM-3 antibodies may have a role as a monotherapy and hold great potential in combination therapy, since they may help overcome resistance that patients may develop against other therapeutics.

[U.S. Patent Application Serial No. 62/004,071, filed May 28, 2014, entitled 'Anti-GITR Antibodies and Methods of Use Thereof.']
Field of Use
The Parties are interested in forming an alliance whose goal is to discover, develop and commercialize a robust portfolio of products to address hematologic and oncologic diseases or conditions.

Checkpoint antibodies effect the immune system, and are now being used in cancer treatment.

The Field means any use of Antibodies for the treatment, control, mitigation, prevention or cure of any or all Indications in humans or animals in the Hematology Field and the Oncology Field

IPSCIO Record ID: 328902

License Grant
Pursuant to the License Agreement, as amended, the University Research Association licensed the exclusive worldwide rights to certain patents on IRX-2 in exchange for royalties.
License Property
IRX-2, a novel cytokine-based therapy, to treat patients with cancer. IRX-2 active constituents, namely Interleukin-2 (IL-2) and other key cytokines are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells.

IRX-2 is an allogeneic, reproducible, primary, cell-derived biologic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as a subcutaneous injection around lymph node beds.

Field of Use
Field of use is for the treatment of cancer.

IPSCIO Record ID: 306496

License Grant
The Licensee was granted an exclusive license to certain Intellectual Property.
License Property
Licensor is the exclusive licensing agent for a University and representing Mayo Clinic’s interests in certain patents and intellectual property rights.  The Intellectual Property encompasses the inhibition of tumor growth using compounds that inhibit QSOX1 enzymatic activity and, specifically, to anti-neoplastic compounds targeting QSOX1 (the parent molecule referred to as SBI-183).

The enzyme Quiescin Sulfhydryl Oxidase 1 (QSOX1) is a master regulator of extracellular matrix remodeling, and its overexpression by tumor cells.  Overexpression of QSOX1 has been unambiguously linked to promoting tumor invasion and metastasis.  It has been discovered that a small molecule SBI-183 inhibited the enzymatic activity of QSOX1 and as a result suppressed tumor cell invasion in vitro and metastasis of breast tumor cells in vivo.

This license is to technology relating to SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis.  Small molecule SBI-183 inhibited the enzymatic activity of QSOX1 and as a result suppressed tumor cell invasion in vitro and metastasis of breast tumor cells in vivo. Through its medicinal chemistry efforts the Licensee synthesized multiple structural analogs of SBI-183 and unveiled SPX-1009 lead compound that demonstrated ten-fold improvement in suppressing invasion and metastasis in several cancer models.

SBI-183 enhances the activity of cytotoxic drugs in vitro.

Field of Use
Licensee was formed to develop a unique biomarker for cancer (QSOX1) as well as cancer diagnostic and therapeutic products based on QSOX1.  Licensee is a research and development company that aims to improve global cancer care through the development of proprietary therapeutics for inhibiting cancer growth and metastasis.

IPSCIO Record ID: 336288

License Grant
Licensor granted Licensee an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term.
License Property
DART platform is a platform that is a designed antibody-based product candidate that have the potential to improve on standard treatments by having one or more of the following attributes (1) multiple specificities; (2) increased abilities to interact with the bodys immune system to fight tumors; (3) capacity to bind more avidly to antigen targets (4) increased potency; (5) reduced immunogenicity or (6) the ability to target and kill cancer cells that are resistant to standard treatments.

DART platform enables us to design multi-specific molecules that seek to exploit different mechanisms.

Field of Use
Field of use is for the treatment of complex biology of cancer.  DART platform is used to create derivatives of antibodies with the ability to bind to two distinct targets instead of a single one found in traditional monoclonal antibodies.

IPSCIO Record ID: 302213

License Grant
Licensor granted to Chinese Licensee an exclusive, sublicensable, royalty-bearing license to Licensor’s patents and know-how to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term of the agreement.
License Property
Enoblituzumab is the Most Advanced Clinical Stage Humanized B7-H3 Antibody as a Potential Immuno-oncology Treatment.  This is a Fc-optimized antibody that targets B7-H3, including in combination with other agents, such as the anti-PD-1 antibody known as MGA012.

Enoblituzumab is a humanized antibody directed at B7-H3, a member of the B7 family of T cell checkpoint regulators. B7-H3 is a promising immuno-oncology drug target as it is widely expressed across multiple tumor types and plays a key role in regulating immune response against cancers. Increasing pre-clinical and clinical evidence suggests that antibodies targeting the two T cell checkpoint molecules—B7-H3 and PD-1—work synergistically in treating cancer. Given B7-H3’s critical role, enoblituzumab has a wide range of cancer applications as either a monotherapy or in combination with PD-1 therapies. At the molecular level, enoblituzumab is engineered to possess an enhanced anti-tumor ADCC function and is at the forefront in global clinical development. Originally developed by Licensor, enoblituzumab has been evaluated in multiple clinical trials as a monotherapy or in combination with CTLA-4 or PD-1 therapies in patients with B7-H3-expressing cancers. Enoblituzumab is also being evaluated in a neoadjuvant Phase 2 study as a single agent in patients with intermediate and high-risk localized prostate cancer.

Field of Use
The license granted is used as an immuno-oncology drug target playing a key role in regulating immune response against cancers.

Licensee and its subsidiaries are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China (the “PRC”) and other countries and regions.

IPSCIO Record ID: 369249

License Grant
Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import Licensed Products solely in the Antibody Targeting Technology Field.

Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the HuMAb Technology and the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import
— Licensed Royalty-Bearing Products solely in the Antibody Targeting Technology Field, and,
— Anti-Mannose Products.

For Hybridoma Cell Lines; Research License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the HuMAb Technology to research, make, have made, transfer physical possession of, but not to sell, lease, offer to sell or lease, or otherwise transfer title to, the Hybridoma Cell Lines.

Licensor grants a non-exclusive, worldwide, license, with the right to sublicense, under the Research Patent to conduct research.

For Research Antibodies License, Licensor grants an exclusive, worldwide license, without the right to sublicense, under the HuMAb Technology and the Licensor Technology to use the Research Antibodies for the sole purpose of determining the antigen with respect to which each Research Antibody was raised.

Licensor, who has incorporated Licensee for business opportunities outside of Licensors core business, irrevocably, perpetually and forever assigns and conveys Licensors entire right, title and interest in and to each of the following Assigned Assets
— Antibody Targeting Patents;
— Antibody Targeting Know-How;
— Anti-Mannose Receptor HuMAb Antibodies;
— the Investigational New Drug Application # 11,508 and related governmental filings, and the right to make any future or foreign related filing on –X-1307;
— all quantities of Biological Materials, including those in the possession or control of counterparties to Assigned Contracts;
— all clinical inventories of –X-1307 in the possession or control of Licensor as of the Effective Date; and
— the agreements that are Assigned Contracts.

License Property
Licensor owns or otherwise controls certain technology, including certain patents and know-how, relating to the use of antibodies in connection with the research and development of vaccines.

Anti-Mannose Product shall mean any pharmaceutical composition or formulation incorporating an Anti-Mannose Receptor HuMAb Antibody.

HuMAb Mouse® shall mean any of Licensors immunizable transgenic mice containing unrearranged human immunoglobulin heavy and light chain transgenes, each inserted into mouse chromosomes, but excluding the Additional Mice. HuMAb Mice® shall mean more than one HuMAb Mouse.

The patents relate to Anti-FcyRI (CD64) antibodies.

Field of Use
The field of use is the Antibody Targeting Technology Field.  The Antibody Targeting Technology Field shall mean the use of an antibody, or fragment thereof, whereby the antibody or fragment serves as a targeting means with respect to an Antigen-Presenting Cell for the purpose of modulating an immune response in any of the following manners
—  an antibody or fragment chemically attached or genetically fused to an antigen (including an antigen that is an antibody, or fragment thereof, that encodes an idiotype antigen), whereby the antibody, or fragment thereof, serves as a targeting means for delivering such antigen to an Antigen-Presenting Cell for the purpose of eliciting an immune response,
— an antibody or fragment chemically attached or genetically fused to a toxin or radionuclide, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such toxin or radionuclide to an Antigen-Presenting Cell for the purpose of decreasing, down-regulating or eliminating the activity of such Antigen-Presenting Cell,
— an antibody or fragment chemically attached or genetically fused to a cytokine, adjuvant, or other immuno-modulatory compound, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such compound to an Antigen-Presenting Cell for the purpose of modulating the activity of such Antigen-Presenting Cell, and
— an antibody, or fragment thereof, alone, whereby the antibody or fragment binds to a particular antigen on the surface of an Antigen-Presenting Cell and through such binding modulates the activity of such Antigen-Presenting Cell.

IPSCIO Record ID: 4497

License Grant
Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses under Licensor's Technology to research, develop, make, have made, use, sell, offer for sale, export and import Licensor's Antibodies and Products in the Field in the Territory.
The license grants rights to all Licensor's mAbs (monoclonal antibodies) in the field of influenza discovered from their CellSpot platform.
License Property
The license provides Licensee with three fully human mAbs that bind, neutralize and protect animals from all strains of H1, H3 and B influenza, and that will also cross bind, neutralize and protect animals from all other seasonal or pandemic influenza strains that may arise (including H5N1 and H7N9).

“Antibody” means any antibody or protein comprising at least one CDR portion thereof (including multi-specific antibodies, single chain antibodies, antibody fragments, domain antibodies and conjugated antibodies) and/or similar binding protein (such as an adnectin), whether human, humanized, chimeric, murine, synthetic or from any other source.

Field of Use
“Field” means all uses for the diagnosis, treatment or prevention of influenza.

IPSCIO Record ID: 369364

License Grant
In consideration of the mutual covenants contained in this Amendment and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree to amend several sections including but not limited to Royalties and Licensee shall have the right, at its sole discretion, either itself or through counsel  of its choice, to control the preparation, filing, prosecution, maintenance and enforcement of all Patents which claim Program Antibodies.
License Property
This agreement is for Collaborative Research. The goal of the Program is to humanize and optimize Candidate Molecules. The plan includes antibody cloning, assay development and validation, design and synthesis of Humanization/Optimization Libraries, Screening, Characterization, Affinity Maturation, Iterative Affinity Maturation and Deliverables. Licensor shall optimize and humanize the Candidate Molecules as set forth in the Research Plan. Licensor shall use its commercially reasonable efforts to perform its obligations under the Program in accordance with the Research Plan. Licensor shall provide the personnel, materials, equipment and other resources required to conduct its obligations under the Program. Licensor shall perform its obligations under the Program in accordance with high scientific and professional standards, and in compliance in all material respects with the requirements of applicable laws and regulations. Licensee shall use its best efforts to actively research, develop and obtain regulatory approvals to market in major markets throughout the world at least one Product.

Product shall mean any product for use in the Field, which is a composition that incorporates one or more Program Antibodies or is derived from one or more Program Antibodies. The Candidate Molecules shall mean, collectively, monoclonal antibody (mAb) HUIV26 and mAb HUI77 as provided by Licensee to Licensor. Materials shall mean the Candidate Molecules, DNA sequence information and the cDNA to encode Candidate Molecules and the hybridoma cell lines expressing the Candidate Molecules. Program Antibody shall mean the optimized and humanized compositions of matter developed under the Program, and the cDNA encoding such compositions of matter, delivered to Licensee.

Field of Use
HUI77 and HUIV26 are anti-angiogenic mouse antibodies discovered using subtractive immunization, which could enable Licensee to pursue the commercialization of these antibodies.

Licensee is developing a family of antibodies that is selective for angiogenesis.  Anti-angiogenesis as a treatment for cancer.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.